Tirzepatide

1.Tirzepatide is a diabetes treatment. It is a dual agonist of glucose-dependent insulin- stimulating polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor. Activating the GLP-1 receptor reduces hunger and thus diet and caloric intake, while activating the GIP receptor reduces diet and caloric intake and increases energy expenditure.

2.In comparison with the hypoglycemic effect of Semaglutide, tirzepatide reduced HBA1c by 2.0-2.3% on average, while semaglutide decreased by 1.9% on average. In terms of fat loss,tirzepatide resulted in an average fat loss of 17 to 25 pounds, compared with 13 pounds for Semaglutide. tirzepatide showed more superior hypoglycemic and weight loss effects than semaglutide.

Linaclotide

1.Linaclotide capsule has the effect of relieving constipation and can treat adult constipated irritable bowel syndrome. Linalotide capsule is a guanylate cyclase agonist with visceral analgesic and secretory effects.

2.At present, only the original research of the drug has been approved for listing in China, the competition degree of the first imitation drug of the drug in China is weak. Linalotide capsule was approved for market in early 2019, and was included in the medical insurance class B variety at the end of the following year. As a result, linalotide capsules achieve rapid dosing. In the first half of 2022, intra-hospital sales exceeded 5.7 million US dollars, an increase of 246%. At present, the domestic market of the drug is exclusive to Astrazeneca, and it is expected that the first domestic imitation drug will be approved as soon as possible.